Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 3/20 | 0.53 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | PDE5A | O76074 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.44 |
| ▸ | TUBB | P07437 | 1/20 | 0.44 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.44 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17298013 | 0.79 | TNKS2 (0.62) | LMNAPOLBGAAALOX12SMN1; SMN2 | |
| SCHEMBL6929589 | 0.78 | KDM4E (0.65) | LMNAPOLBGAAALOX12SMN1; SMN2 | |
| SCHEMBL29900514 | 0.78 | KDM4E (0.65) | LMNAPOLBGAAALOX12SMN1; SMN2 | |
| SCHEMBL28097943 | 0.76 | POLB (0.56) | LMNAPOLBGAAALOX12SMN1; SMN2 | |
| SCHEMBL28097938 | 0.76 | PIM1 (0.57) | LMNAPOLBGAAALOX12SMN1; SMN2 | |
| SCHEMBL19104694 | 0.76 | LMNA (0.54) | LMNAPOLBGAAALOX12SMN1; SMN2 | |
| SCHEMBL29141394 | 0.74 | GAA (0.56) | LMNAPOLBGAAALOX12SMN1; SMN2 | |
| SCHEMBL1885790 | 0.72 | LMNA (0.43) | LMNAPOLBGAAALOX12SMN1; SMN2 | |
| SCHEMBL13343406 | 0.72 | ALOX15 (0.51) | LMNAPOLBSMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL24807720 | 0.72 | LMNA (0.50) | LMNAPOLBGAAALOX12SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1689724-B1 | QUINAZOLINONE COMPOUNDS AS ANTICANCER AGENTS | NOVARTIS AG (CH) | 2011-12-21 | — | — | EP | disclosed |
| EP-1689724-B1 | QUINAZOLINONE COMPOUNDS AS ANTICANCER AGENTS | NOVARTIS AG (CH) | 2011-12-21 | — | — | EP | disclosed |
| US-20110190293-A1 | Quinazolinone Compounds as Anticancer Agents | CHIRON CORPORATION | 2011-08-04 | — | — | US | disclosed |
| US-20110190293-A1 | Quinazolinone Compounds as Anticancer Agents | CHIRON CORPORATION | 2011-08-04 | — | — | US | disclosed |
| US-20110190293-A1 | Quinazolinone Compounds as Anticancer Agents | CHIRON CORPORATION | 2011-08-04 | — | — | US | disclosed |
| US-7939539-B2 | Kinesin spindle protein (KSP) inhibitors; 2-substituted 4-(thio)oxo-3,4-dihydroquinazolines; use in combination with other anticancer agents | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2011-05-10 | — | — | US | disclosed |
| US-7939539-B2 | Kinesin spindle protein (KSP) inhibitors; 2-substituted 4-(thio)oxo-3,4-dihydroquinazolines; use in combination with other anticancer agents | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2011-05-10 | — | — | US | disclosed |
| US-7939539-B2 | Kinesin spindle protein (KSP) inhibitors; 2-substituted 4-(thio)oxo-3,4-dihydroquinazolines; use in combination with other anticancer agents | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2011-05-10 | — | — | US | disclosed |
| CN-1886384-A | Quinazolinone compounds as anticancer agents | CHIRON CORP (US) | 2006-12-27 | — | — | CN | disclosed |
| EP-1689724-A1 | QUINAZOLINONE COMPOUNDS AS ANTICANCER AGENTS | Chiron Corporation (US) | 2006-08-16 | — | — | EP | disclosed |
| US-20050209254-A1 | Quinazolinone compounds as anticancer agents | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2005-09-22 | — | — | US | disclosed |
| WO-2005051922-A1 | QUINAZOLINONE COMPOUNDS AS ANTICANCER AGENTS | CHIRON CORPORATION (US) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190293-A1 | Quinazolinone Compounds as Anticancer Agents | TP53, NQO2, TOP1 | LMNA 1850/4885POLB 597/4885GAA 366/4885 |
| US-20050209254-A1 | Quinazolinone compounds as anticancer agents | TP53, NQO2, TOP1 | LMNA 1850/4885POLB 597/4885GAA 366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.